

**NEWS RELEASE**  
TSX Venture Exchange: MEV

## **Study in Peer-Reviewed Medical Journal Confirms Ability of Medical Ventures' Metricath<sup>®</sup> Device to Detect Renal Stent Under-Expansion**

***Study Published in 'Journal of Invasive Cardiology' Shows Stent Under-Expansion in Renal Artery Procedures, A Risk Factor for Restenosis, Is Common Without Vascular Measurement***

**June 18, 2008 – Richmond, BC, Canada** – Medical Ventures Corp. (TSXV: MEV), a company developing and marketing specialty vascular devices, announced today that a clinical study published in the June 2008 issue of the *Journal of Invasive Cardiology* (JIC) shows its Metricath<sup>®</sup> arterial measurement device can help physicians optimize the deployment of stents in renal vascular procedures. Stent under-expansion is a common occurrence in vascular intervention and is believed to contribute to stent restenosis. In this study, 90% of the stents placed without the use of vascular measurement technology were shown to be under-expanded. The 2007 clinical study was directed by Dr. Raed Aqel, an interventional cardiologist at University of Alabama-Birmingham Hospital and Birmingham Veterans Affairs Medical Center.

According to the study's authors, renal artery stent restenosis remains a significant impediment that in part is attributable to suboptimal stent deployment. This study was designed to test whether optimal stent deployment during renal artery interventions can be achieved using the Metricath System. Stent dimensions were measured in 16 patients with 20 renal lesions. First, stents were implanted according to typical procedures that rely solely on visual assessments during the angiography process to determine expansion. Researchers then used the Metricath device to measure the interior of the stents to determine if the anticipated expansion had actually been achieved. In the study, it was found that 18 of the 20 stents that had appeared as fully expanded by angiography were found using Metricath to be under-expanded. In cases where stent under-expansion was detected, additional steps were taken to further expand the stents.

The importance of using vascular measurement tools to achieve optimal stent expansion is suggested by Dr. Aqel's observation that "Metricath guidance during renal interventions disclosed a large proportion of under-deployed stents that were further optimized by adjunctive intervention."

Alexei Marko, Medical Ventures' president and chief operating officer, said: "We are very pleased to see Dr. Aqel's research appear in a respected medical journal such as the *Journal of Interventional Cardiology*. We believe that dissemination of this type of research in peer-reviewed publications can help educate the medical community to the frequency of stent under-expansion and the role that vascular measurement can play in achieving optimal outcomes for patients. The study also highlights our Metricath System, which is a safe, inexpensive and easy-to-use device. It enables physicians to obtain vascular measurement data rapidly and cost effectively to optimize stent expansion."

The study and an accompanying JIC commentary is posted on the JIC website, at [www.invasivecardiology.com/article/8822](http://www.invasivecardiology.com/article/8822)

The Journal of Invasive Cardiology, ISSN: 1042-3931. Volume 20, Issue 6, June 2008, Pages 270-276.



13700 Mayfield Place, Suite 2135  
Richmond, BC V6V 2E4 Canada  
Phone: 604-270-4344  
Fax: 604-270-4384  
[www.medical-ventures.com](http://www.medical-ventures.com)

### **About Medical Ventures Corp.**

Medical Ventures Corp. (soon to be re-named Neovasc Inc.) develops, manufactures and markets medical devices for the rapidly growing vascular and surgical marketplace. The company's products help doctors treat a wide range of health conditions, including vascular diseases and obesity. They include the Metricath<sup>®</sup> arterial and in-stent measurement system, and PeriPatch<sup>™</sup> surgical tissue and staple line reinforcement products. Medical Ventures also has a contract medical device manufacturing unit. Medical Ventures is expected to finalize the acquisition of two medical technology companies and change the company's name to Neovasc Inc. by July 1, 2008. For more information, please visit: [www.medical-ventures.com](http://www.medical-ventures.com).

###

*Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continues," "estimates," "expects," and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with Canadian securities regulators. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements.*

### **Investor contact**

Caren Holtby, Investor Relations Manager  
Medical Ventures Corp.  
604-805-8772 or [choltby@medical-ventures.com](mailto:choltby@medical-ventures.com)

### **Media contacts**

Jessica Ruffen, Communications Manager  
Medical Ventures Corp.  
604-248-4136 or [jruffen@medical-ventures.com](mailto:jruffen@medical-ventures.com)

GendeLLindheim BioCom Partners  
Barbara Lindheim  
212-918-4650 or [blindheim@biocompartners.com](mailto:blindheim@biocompartners.com)